Effects of postoperative treatment with chemotherapy and cellular immunotherapy on patients with colorectal cancer

Abstract

BACKGROUND

The outcome of surgical treatment for colorectal cancer (CRC) remains unsatisfactory and warrants further exploration and optimization.

AIM

To clarify the impact of chemotherapy plus cellular immunotherapy [dendritic cell-cytokine-induced killer (DC-CIK) cell immunotherapy] on patients after CRC surgery and to explore the mediating variables.

METHODS

A total cohort of 121 patients who underwent CRC surgery between July 2020 and October 2023 were selected. The sample comprised a control group of 55 patients who received the XELOX chemotherapy regimen and a research group of 66 patients who received XELOX + DC-CIK immunotherapy. We performed comparative analyses of the clinical and pathological data of the two groups, including efficacy, the incidence of adverse events (diarrhea, myelosuppression, gastrointestinal reactions, and peripheral neuritis), serum levels of tumor markers [carcinoembryonic antigens and carbohydrate antigens (CA)19-9 and CA242], and T-cell subsets [cluster of differentiation (CD)3⁺, CD3⁺ CD4⁺, CD3⁺ CD8⁺, natural killer (NK), and NK T cells]. We also conducted preliminary univariate and multivariate analyses of the variables that affected the efficacy of the treatments.

RESULTS

We found a significantly higher rate of treatment efficacy in the research group than in the control group, with a statistically lower incidence of adverse events. Both groups showed a reduction in serum tumor markers after treatment but there was no marked intergroup difference. After treatment, the various T-cell subgroup indicators in the control group were significantly lower than those in the research group. The indices of T-cell subsets in the research group showed no significant change from preoperative levels. Univariate analysis revealed a significant correlation between TNM staging, tumor differentiation, and the rates of nonresponse to treatment in CRC patients after surgery. Multivariate results indicated that the treatment approach significantly affected the efficacy of postoperative CRC treatment.

CONCLUSION

We concluded that XELOX + DC-CIK immunotherapy for postsurgical CRC patients offers reduced rates of treatment-induced adverse events, improved curative effects, enhanced immunity, and increased physiological antitumor responses.

Key Words: Analysis of variables affecting outcomes; Cellular immunotherapy; Chemotherapy; Colorectal cancer; Clinical effects

Core Tip: Adjuvant postoperative therapy for colorectal cancer (CRC) maximizes surgical outcomes while significantly reducing CRC-related mortality. This study analyzes the efficacy of the XELOX regimen combined with dendritic cell-cytokine-induced killer (DC-CIK) cell immunotherapy for postoperative CRC patients and the mediating variables, aiming to provide a useful clinical reference to optimize the efficacy of postoperative CRC treatment. Through a comparative analysis of the XELOX chemotherapy regimen vs XELOX regimen plus DC-CIK immunotherapy therapy across multiple outcome and safety indices, including efficacy, adverse event rates, serum tumor marker levels, and T-cell subset levels, the combination regimen is confirmed to offer greater efficacy than a chemotherapy regimen alone, enhancing patient immunity, increasing physiological antitumor activity, and providing improved treatment safety.

INTRODUCTION

Colorectal cancer (CRC) is a common malignancy of the digestive system. Predisposing factors include obesity, a sedentary lifestyle, drinking, smoking, and red meat consumption[1]. In 2020, there were 1.93 million cases of CRC worldwide, with nearly 1 million deaths; and this is expected to grow to 3.2 million annual cases by 2040[2]. Although overall CRC mortality rates have shown a downward trend, confirmed cases are becoming gradually more concentrated in younger age groups, and at more advanced stages[3]. Previous studies have shown mortality rates of 13% in CRC patients at stage I/II, 47% in patients at stage III, and nearly 90% in patients at stage IV[4]. Surgery is the primary treatment for CRC, but postoperative adjuvant therapy is often required to avoid postoperative recurrence and metastasis[5-7]. Exploring adjuvant therapies for patients after CRC surgery not only optimizes the effects of surgical treatment but also provides a significant reduction in CRC-related mortality rates.

Combined postoperative adjuvant chemotherapy and radiotherapy have demonstrated beneficial effects on the elimination of tumor cells and residual lesions that improve patient survival rates. However, this approach is associated with an increased incidence of adverse events such as gastrointestinal reactions (GIRs), immune system damage, and even myelosuppression[8,9]. After surgery and adjuvant chemotherapy, patients with CRC are more severely immunosuppressed[10]. Cellular immunotherapy has been used in previous research as a complement to conventional therapy that promotes immune function recovery and assists in the destruction of residual chemotherapy-resistant cancer cells[11]. Previous studies have confirmed the clinical effectiveness of adoptive cell immunotherapy, including cytokine-induced killer (CIK) cells, natural killer (NK) cells, T-cell receptor T cells, and tumor-infiltrating lymphocytes[12]. Among these, CIK cells have demonstrated particular clinical effectiveness in the treatment of various tumors, with low toxicity, rapid proliferation, and increased breadth and strength of antitumor activity in the body[13,14]. Dendritic cell (DC)-CIK cells are a novel antitumor immunotherapy that, when combined with chemotherapy, contributes to a higher 6-month quality of life and 2-year survival rate in CRC patients after radical resection[15].

This study analyzes the effects of XELOX + DC-CIK immunotherapy in postsurgical CRC patients and the variables that moderate these effects. We aim to provide an effective clinical reference that optimizes postoperative treatment efficacy and prognosis after CRC surgery.

MATERIALS AND METHODS

General data

A retrospective analysis was performed using data from 121 postoperative CRC patients treated at the General Hospital of Northern Theater Command, Shenyang, China, between July 2020 and October 2023. The 55 patients in the control group received postoperative chemotherapy with the XELOX regimen, while the 66 patients in the research group received XELOX + DC-CIK immunotherapy.

Patient selection criteria

The inclusion criteria for this study were as follows: Meeting the diagnostic criteria for CRC[16]; pathologically confirmed as stage II or III; receiving treatment for the first time; Karnovsky Performance Scale scores ≥ 60; survival durations > 8 weeks; unilateral lesions; patients or their families having been fully informed about the condition, treatment plan, and possible adverse reactions before treatment; no contraindications to the treatment regimens used in this study.

The exclusion criteria were: Intolerance to chemotherapy; a history of allergy to biologics; long-term use of immunosuppressants; concomitant psychiatric illness; heart, lung, or kidney insufficiency; hematological diseases; immune system disorders; other malignant tumors; and pregnancy or lactation.

Treatment methods

The control group underwent the XELOX chemotherapy regimen. The specifics of each cycle of this regimen are oxaliplatin (130 mg/m²) administered intravenously on the first day and capecitabine (1000 mg/m², twice daily) given orally from day 1 to day 14. Depending on their condition, the patient receives 6-8 cycles of chemotherapy, with each cycle lasting 21 days.

DC-CIK cell cultures were performed 2 days before the start of chemotherapy in research group patients. The research group received the same chemotherapy regimen as the control group but initiated from day 3 of the regimen. The additional immunotherapy received by the research group was performed as described below.

First, autologous tumor cell antigens were prepared: Tumor tissue from the patient was ground into a pulp, digested by collagenase into a single-cell suspension, and then separated using a separating medium to obtain primary CRC cells. After several passages, the cells were collected and washed three times in a row. They were then lysed, and the supernatant was collected by filtration and stored for later use. Subsequently, peripheral blood was collected and centrifuged to obtain mononuclear cells, which were inoculated in a lymphocyte culture medium. The suspended cells were collected. The adherent cells were added to the medium, with granulocyte-macrophage colony-stimulating factor and interleukin-4. On day 7, autologous tumor cell antigens were added, and DCs were obtained after sensitization. Finally, the suspended cells were added to a lymphocyte culture medium containing CIK cell cytokines, and rhIL-2. Antihuman cluster of differentiation (CD)3 monoclonal antibodies were added a day later until co-culture with DCs on day 7 for the final collection of DC-CIK cells. Negative results on tests for bacteria, fungi, endotoxins, and mycoplasma were required and established before transfusion. The viability rate of the reinfused cells was > 95%, and the number of cells was ≥ 1.0 × 10⁹ cells/time. DC-CIK cells were cultured until day 13, at which point, they were confirmed to be free of bacterial fungi and endotoxins by relevant tests. The cells were then washed three times with sterile normal saline and suspended in 200 mL of normal saline containing 2% albumin. Reinfusion was performed once a day for 3 days for a duration of 1.5 hours, with no fewer than 3 × 10⁹ DC-CIK cells per infusion. Each patient received two cycles of DC-CIK cell therapy.

Evaluated outcomes

Efficacy: Short-term treatment efficacy was determined according to the Response Evaluation Criteria in Solid Tumors. This was classified into response categories as follows: Complete response (CR; disappearance of all lesions for ≥ 4 weeks), partial response (PR; a decrease of > 30% in the largest lesion diameter that persisted for ≥ 4 weeks), progressive disease (PD; the sum of the largest lesion diameters increased by more than 20% and remained elevated for ≥ 4 weeks), or stable disease (SD; a condition that falls between PR and PD). The disease control rate (DCR) was defined as the sum of the percentages of CR + PR + SD.

Incidence of adverse events: Adverse reactions were evaluated per the National Cancer Institute Common Terminology Criteria for Adverse Events[17]. The adverse events observed in our cohort were diarrhea, myelosuppression, GIRs, and peripheral neuritis. In each group, we recorded the number of patients who suffered from these adverse events and calculated the incidence rate. Targeted treatment for the alleviation of these adverse events was provided in a timely manner.

Serum tumor marker levels: Before and after treatment, 5 mL of fasting venous blood was collected from the patients in both groups. Serum was extracted from the samples by centrifugation and subjected to enzyme-linked immunosorbent assays of carcinoembryonic antigen (CEA), carbohydrate antigen (CA)19-9, and CA242.

T-cell subset levels: The levels of T-cell subsets (CD3⁺, CD3⁺ CD4⁺, CD3⁺ CD8⁺, NK, and NK T) were determined by flow cytometry. These were considered representative of patient immune function.

Statistical analysis

Quantitative data, represented by (mean ± SD), were analyzed for intergroup differences using independent samples t-tests, while intragroup differences were determined using paired t-tests. Count data, expressed as ratios (percentages), were compared between groups using χ² tests. The minimum sample size required per group was determined to be approximately 50. This was ascertained using the binomial proportion sample size estimation formula. The experimental data were analyzed using IBM SPSS Statistics for Windows, v. 19.0 (IBM Corp., Armonk, NY, United States) software, with P values < 0.05 considered statistically significant.

RESULTS

Baseline data of the two groups

There were no significant differences between the research group and the control group in baseline characteristics. These included age, sex, onset site, pathological type, clinical stage, and tumor differentiation (P > 0.05; Table 1).

Table 1 Baseline data of the colorectal cancer cohort included in this study.

Baseline data	Control group (n = 55)	Research group (n = 66)	χ2/t	P value
Age (years), mean ± SD	57.09 ± 7.75	56.41 ± 11.14	0.382	0.703
Sex, n (%)			0.111	0.740
Male	30 (54.55)	34 (51.52)
Female	25 (45.45)	32 (48.48)
Onset site, n (%)			0.186	0.666
Colon	27 (49.09)	35 (53.03)
Rectum	28 (50.91)	31 (46.97)
Pathological type, n (%)			0.043	0.836
Adenocarcinoma	49 (89.09)	58 (87.88)
Other	6 (10.91)	8 (12.12)
Clinical stage, n (%)			0.029	0.864
II	35 (63.64)	41 (62.12)
III	20 (36.36)	25 (37.88)
Differentiation, n (%)			0.021	0.885
Moderately- or well-differentiated	39 (70.91)	46 (69.70)
Poorly differentiated	16 (29.09)	20 (30.30)

Curative treatment effects in the two groups

The control group’s DCR of 65.45% was significantly lower than the 81.82% DCR of the research group (P < 0.05).

Our univariate analysis of the factors affecting postoperative treatment efficacy in CRC patients showed treatment efficacy to be significantly correlated with clinical stage, differentiation degree, and treatment approach (P < 0.05). Multivariate analysis found only the treatment approach to significantly affect postoperative treatment efficacy (P < 0.05; Table 2, Table 3 and Table 4).

Table 2 Efficacy of the postoperative treatments in the two colorectal cancer patient groups, n (%).

Curative effect	Control group (n = 55)	Research group (n = 66)	χ2	P value
CR	15 (27.27)	27 (40.91)	2.462	0.117
PR	11 (20.00)	24 (36.36)	3.907	0.048
SD	10 (18.18)	3 (4.55)	5.817	0.016
PD	19 (34.55)	12 (18.18)	4.215	0.040
DCR	36 (65.45)	54 (81.82)	4.215	0.040

The control group was treated with the XELOX chemotherapy regimen and the research group with XELOX + the dendritic cell-cytokine-induced killer immunotherapy regimen. CR: Complete response; DCR: Disease control rate; PD: Progressive disease; PR: Partial response; SD: Stable disease.

Table 3 Univariate analysis of the variables that mediate postoperative treatment efficacy in colorectal cancer patients, n (%).

Baseline data	Effective treatment group (n = 90)	Ineffective treatment group (n = 31)	χ2	P value
Age (years)			0.402	0.526
< 60	58 (64.44)	18 (58.06)
≥ 60	32 (35.56)	13 (41.94)
Sex			0.340	0.560
Male	49 (54.44)	15 (48.39)
Female	41 (45.56)	16 (51.61)
Onset site			0.216	0.642
Colon	45 (50.00)	17 (54.84)
Rectum	45 (50.00)	14 (45.16)
Pathological type			0.072	0.788
Adenocarcinoma	80 (88.89)	27 (87.10)
Other	10 (11.11)	4 (12.90)
Clinical stage			10.363	0.001
I-II	64 (71.11)	12 (38.71)
III	26 (28.89)	19 (61.29)
Differentiation			12.550	< 0.001
Moderately- or well-differentiated	71 (78.89)	14 (45.16)
Poorly differentiated	19 (21.11)	17 (54.84)
Treatment approach			4.215	0.040
XELOX	36 (40.00)	19 (61.29)
XELOX + DC-CIK	54 (60.00)	12 (38.71)

DC-CIK: Dendritic cell-cytokine-induced killer.

Table 4 Multivariate analysis of the variables that mediate postoperative treatment efficacy in colorectal cancer patients.

Variable	β	SE	Wald	P value	OR	95%CI
Clinical stage	0.114	0.443	0.066	0.797	1.121	0.470-2.673
Differentiation	−0.056	0.473	0.014	0.905	0.945	0.374-2.390
Treatment approach	0.867	0.427	4.115	0.042	2.379	1.030-5.495

95%CI: 95%confidence interval; OR: Odds ratio; SE: Standard error.

Adverse events in the two groups

All adverse events in both groups were of grades 0 to 2. The adverse events observed were diarrhea, myelosuppression, GIRs, and peripheral neuritis. We found a significantly lower incidence of these adverse events in the research group vs the control group (P < 0.05; Table 5).

Table 5 Adverse events in the two colorectal cancer treatment groups, n (%).

Adverse event	Control group (n = 55)	Research group (n = 66)	χ2	P value
Diarrhea	11 (20.00)	5 (7.58)	4.036	0.045
Myelosuppression	20 (36.36)	10 (15.15)	7.239	0.007
Gastrointestinal reaction	19 (34.55)	9 (13.64)	7.374	0.007
Peripheral neuritis	7 (12.73)	2 (3.03)	4.097	0.043

The control group was treated with the XELOX chemotherapy regimen and the research group with XELOX + the dendritic cell-cytokine-induced killer immunotherapy regimen.

Serum tumor marker levels in the two groups

Similar levels of the serum tumor markers CEA, CA19-9, and CA242 were detected in both groups before treatment (P > 0.05). The levels of all three markers were significantly lower in both groups after treatment (P < 0.05), but with no statistically significant intergroup difference (P > 0.05; Figure 1).

Figure 1 Serum tumor marker levels in the two colorectal cancer treatment groups. The control group was treated with the XELOX chemotherapy regimen and the research group with XELOX + the dendritic cell-cytokine-induced killer immunotherapy regimen. A: Pre- and posttreatment carcinoembryonic antigen levels in the two groups. B: Pre- and posttreatment carbohydrate antigens (CA)19-9 levels in the two groups; C: Pre- and posttreatment CA242 levels in the two groups. ^aP < 0.05 compared to pre-treatment levels; ^bP < 0.01 compared to pre-treatment levels. CEA: Carcinoembryonic antigens; CA: Carbohydrate antigens.

T-cell subset levels in the two groups

The main T-cell subsets detected in our cohort were CD3⁺, CD3⁺ CD4⁺, CD3⁺ CD8⁺, NK, and NK T cells. There was little difference between the two groups in the pre-treatment levels of these T-cell subsets (P > 0.05). In the research group, there was no significant difference in the levels of these indicators before and after treatment (P > 0.05); while significant posttreatment reductions were observed in the control group (P < 0.05). After treatment, T-cell subset levels were statistically lower in the control group than in the research group (P < 0.05; Figure 2).

Figure 2 Pre- and posttreatment levels of T-cell subsets in the two colorectal cancer treatment groups. The control group was treated with the XELOX chemotherapy regimen and the research group with XELOX + the dendritic cell-cytokine-induced killer immunotherapy regimen. A: Pre- and posttreatment CD3⁺ levels in the two groups; B: Pre- and posttreatment CD3⁺ CD4⁺ levels in the two groups; C: Pre- and posttreatment CD3⁺ CD8⁺ levels in the two groups; D: Pre- and posttreatment natural killer (NK) cell levels in the two groups; E: Pre- and posttreatment NK T-cell levels in the two groups. ^aP < 0.05 compared to pre-treatment levels; ^bP < 0.01 compared to pre-treatment levels; ^cP < 0.05 compared to control group levels. CD: Cluster of differentiation; NK: Natural killer.

DISCUSSION

The colorectum is not only an important component of the digestive system; it is also an important element of the immune system, mediating the body’s innate and adaptive immune responses[18]. CRC tumors are infiltrated by effector-memory lymphocytes, and further breakthroughs are needed in the immunotherapies used to treat this condition[19]. This study evaluated the outcomes of treatment with adjuvant XELOX + DC-CIK immunotherapy after CRC surgery and assessed the factors that mediate its curative effects.

We found a statistically higher DCR in the research group vs the XELEX-only control group (81.82% vs 65.45%). This was in concordance with the findings of Wang et al., which showed that DC-CIK immunotherapy improves the overall chemotherapy response rate in CRC patients and increases the CD4 T-cell count, enhancing patient immunity[20]. Previous studies have shown that DC-CIK induces significantly greater antitumor activity than CIK alone, accelerating T-cell proliferation, enhancing tumor cell destruction, and strengthening the body’s immune responses. Together, these responses effectively inhibit tumor growth[21,22].

Our univariate analysis found clinical stage III, low differentiation, and the XELOX treatment regimen alone to be significantly correlated with treatment failure in postoperative CRC patients. Multivariate analysis confirmed that the treatment approach was a risk factor affecting the postoperative efficacy of CRC, suggesting that the addition of DC-CIK immunotherapy to XELOX chemotherapy can significantly improve treatment efficacy in postoperative CRC patients. In terms of safety, our research group showed a statistically lower incidence of adverse events (including diarrhea, myelosuppression, GIRs, and peripheral neuritis) than the control group, indicating that DC-CIK immunotherapy may offset the drug-related side effects associated with XELOX treatment. In line with our research results, a meta-analysis by Lan et al[23] found that DC-CIK immunotherapy enhanced the efficacy of chemotherapy for solid cancers, including CRC, with reasonable safety and no specific or severe side effects.

Our pathological investigation found that the serum tumor markers, CEA, CA19-9, and CA242 levels were statistically decreased by both XELOX and the combined therapy, but there were no significant intergroup differences, either before or after treatment, indicating equivalent inhibitory effects. We found marked postintervention reductions in patient levels of the T-cell subsets CD3⁺, CD3⁺ CD4⁺, CD3⁺ CD8⁺, NK, and NK T cells in the control group. These were statistically lower than the levels observed in the research group. There was no significant posttreatment change in the above indicators in the research group. This indicates that DC-CIK immunotherapy can significantly alleviate XELOX-related immunosuppression, with significantly improved immune function seen in postsurgical CRC patients. Xu et al[24] found that combining chemotherapy with DC-CIK immunotherapy statistically increased the percentages of CD3⁺, CD8⁺, NK, and NKT cells in CRC patients compared with simple adjuvant chemotherapy and palliative treatment. Supporting our findings, they also observed good maintenance effects on patient immune function. Pan et al[25] found that CIK immunotherapy combined with first-line chemotherapy effectively prolonged overall survival and progression-free survival in patients with metastatic CRC. Li et al[26] also demonstrated that the XELOX + DC-CIK immunotherapy regimen helps to prolong the survival of patients after CRC surgery. They identified a correlation between the primary tumor expression of SLAMF7 and treatment efficacy.

This study had some limitations that should be addressed in future studies. First, there was no follow-up. Data on patient recurrence and overall survival would have enabled evaluation of the long-term effects and sustainability of treatment benefits. Second, detailed information on the severity of adverse events and specific management measures were not provided. Such information needs to be provided in future research to facilitate our understanding of the safety of DC-CIK immunotherapy and related interventions. Finally, this study was subject to the limitations inherent in retrospective designs. Future clinical trials would strengthen the validity of our results.

CONCLUSION

We found XELOX + DC-CIK immunotherapy for postoperative CRC patients to demonstrate significantly greater clinical efficacy and safety than XELOX alone. The adoption of this treatment approach may provide statistical improvement in the DCR, reduce the risk of adverse events, and enhance patients’ immune response to the disease. To ensure the therapeutic effectiveness of postoperative treatment, CRC patients should be screened, and those at clinical stage II and those with medium to high differentiation favored for treatment with the XELOX + DC-CIK immunotherapy regimen due to their particular responsiveness to this approach. However, our findings are generalizable to the broader population of CRC patients beyond the study cohort and can be applied in clinical practice.